Oligometastatic disease may benefit from aggressive multimodal therapy.

Oligometastatic patients with esophageal, gastro-esophageal junction, and gastric cancers experience improved outcomes with aggressive multimodal therapies. Research indicates that combining systemic therapy with surgical resection of primary tumors and metastases enhances prognosis. Notably, patients with oligometastatic cancer at the esophago-gastric junction showed potential for curative treatment. These findings suggest that current treatment paradigms should be updated to incorporate multimodal approaches, pending verification from ongoing prospective trials for future guideline inclusion.